News
3/18/2024 Study RNC Pharma and Medvestnik: 63% of Russian Doctors Back Initiative to Allow Early Retirement in Private Hospitals, 35% Against
49.2% of Russian physicians fully support the initiative to allow doctors working in private medical institutions early retirement, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.
3/13/2024 Study by RNC Pharma and Medvestnik: 37% of Russian Doctors Do Not Believe in Quick Launch of New System of Remuneration, 46% Say New System Will Lead to Lower Salaries
Most Russian physicians remain pessimistic regarding the new system of remuneration. Only 9.6% of the doctors expect higher salaries soon, saying that the chances of implementing the project are high, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. Another 15.7% of the respondents believe that the system will be launched only if the economic situation improves. Finally, 21.6% do not expect any rapid changes, saying that even if it is launched as quickly as possible, it will take several years before the system launches nationwide.
3/11/2024 Study by RNC Pharma and Medvestnik: 53% of Russian Doctors Against ICD-11 Implementation
Most Russian physicians (52.8%) support the suspension of ICD-11 implementation in the country, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. In particular, 34.4% fully support the suspension, believing that a number of ICD-11 sections promote the LGBT agenda and contradict medical science. Another 18.4%, while saying that the suspension of ICD-11 in its current form may be appropriate, believe that the implementation can be resumed provided that the controversial sections are excluded.
3/11/2024 Study by RNC Pharma and Medvestnik: 53% of Russian Doctors Against ICD-11 Implementation
Most Russian physicians (52.8%) support the suspension of ICD-11 implementation in the country, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors. In particular, 34.4% fully support the suspension, believing that a number of ICD-11 sections promote the LGBT agenda and contradict medical science. Another 18.4%, while saying that the suspension of ICD-11 in its current form may be appropriate, believe that the implementation can be resumed provided that the controversial sections are excluded.
3/7/2024 RNC Pharma: Online Sales on Veterinary Market Double in January 2024
In January 2024, 2.1 billion rubles’ worth of veterinary drugs were sold on the Russian veterinary retail market (retail prices, VAT included), up 11.8% from January 2023. In physical terms, 16.5 million minimum dosage units (MDU) were sold, up 7.6% from January 2023.
2/22/2024 RNC Pharma: Russian Pharma Retail Ready to Resume Investing Activities
Russian Pharmacy Chain Rankings in 2023
2/15/2024 Inflation Rates in the Russian Pharmaceutical Retail Market in 2023
In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The highest price growth rates were seen in early 2023 (Fig. 1); as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023.
2/14/2024 RNC Pharma: Market Share of Top Russian Pharma Distributors Grows
Russian Pharmaceutical Distributor Rankings in 2023
2/13/2024 RNC Pharma: Analog Mercury Thermometers Most Stable in Demand in 2023
In 2023, 9.9 million medical thermometers worth 3.3 billion rubles (retail prices, VAT included) were sold on the Russian retail market (online sales included), down 12% in physical and down 15.7% in monetary terms from 2022.
2/9/2024 RNC Pharma: 2023 Retails Sales of Russian-Made Enteral Nutrition Up 69%
In 2023, the sales of enteral nutrition on the Russian retail market (e-com included) were 4.8 billion rubles (retail prices, VAT included), or 12.4 million packages. The sales went up 12.2% in monetary terms, but went down 1.9% in physical terms, which is a clear indicator that the market was able to grow last year only because of inflation.
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2015
- 2014
- 2013